NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.76 +0.05 (+0.27 %) (As of 12/14/2018 03:20 PM ET)Previous Close$18.71Today's Range$18.33 - $18.975052-Week Range$11.45 - $32.00Volume164,832 shsAverage Volume270,802 shsMarket Capitalization$1.01 billionP/E Ratio-5.11Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. The company has a development agreement with Enable Injections, Inc. to develop wearable devices for subcutaneous delivery of high-volume therapeutics. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky. Receive APLS News and Ratings via Email Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLS Previous Symbol CUSIPN/A Webwww.apellis.com Phone502-241-4114 Debt Debt-to-Equity Ratio0.14 Current Ratio14.90 Quick Ratio14.91 Price-To-Earnings Trailing P/E Ratio-5.11 Forward P/E Ratio-7.88 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.96 per share Price / Book6.34 Profitability EPS (Most Recent Fiscal Year)($3.67) Net Income$-51,000,000.00 Net MarginsN/A Return on Equity-61.87% Return on Assets-51.13% Miscellaneous Employees39 Outstanding Shares56,240,000Market Cap$1.01 billion OptionableNot Optionable Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions What is Apellis Pharmaceuticals' stock symbol? Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS." How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals Inc (NASDAQ:APLS) posted its earnings results on Tuesday, November, 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.69) by $0.05. View Apellis Pharmaceuticals' Earnings History. When is Apellis Pharmaceuticals' next earnings date? Apellis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Apellis Pharmaceuticals. What price target have analysts set for APLS? 5 analysts have issued 1-year target prices for Apellis Pharmaceuticals' shares. Their forecasts range from $34.00 to $53.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $41.40 in the next twelve months. This suggests a possible upside of 120.7% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals. What is the consensus analysts' recommendation for Apellis Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals. What are Wall Street analysts saying about Apellis Pharmaceuticals stock? Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock: 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (11/16/2018) 2. Cantor Fitzgerald analysts commented, "Apellis is developing APL-2, an investigational C3 inhibitor for complement-mediated diseases. In our view, APLS shares offer a compelling risk-reward profile due to the large market potential and compelling efficacy profile in PNH and geographic atrophy (GA). Valuation Summary We arrive at our 12-month price target of $53/share by assessing the after-tax, risk- adjusted NPV of potential future cash flows from APL-2." (9/4/2018) Has Apellis Pharmaceuticals been receiving favorable news coverage? News headlines about APLS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are some of Apellis Pharmaceuticals' key competitors? Some companies that are related to Apellis Pharmaceuticals include GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), FibroGen (FGEN), Array Biopharma (ARRY), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Blueprint Medicines (BPMC) and Endo International (ENDP). Who are Apellis Pharmaceuticals' key executives? Apellis Pharmaceuticals' management team includes the folowing people: Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 46)Dr. Pascal Deschatelets, Co-Founder & COO (Age 48)Mr. Timothy E. Sullivan, CFO & Treasurer (Age 47)Dr. Federico Grossi M.D., Ph.D., Co-Founder & Sr. VP of Clinical Devel. (Age 44)Mr. David O. Watson, Gen. Counsel & VP of Corp. Devel. (Age 45) When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.08%), Vanguard Group Inc. (2.52%), Vanguard Group Inc (2.52%), Vivo Capital LLC (2.41%), Victory Capital Management Inc. (2.40%) and Jennison Associates LLC (1.02%). Company insiders that own Apellis Pharmaceuticals stock include David O Watson, Global Strategic Fund I Venbio, Lukas Scheibler and Morningside Venture Investment. View Institutional Ownership Trends for Apellis Pharmaceuticals. Which major investors are selling Apellis Pharmaceuticals stock? APLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Vivo Capital LLC, Sofinnova Ventures Inc, Alliancebernstein L.P., JPMorgan Chase & Co., TIAA CREF Investment Management LLC, Virtus ETF Advisers LLC and Federated Investors Inc. PA. View Insider Buying and Selling for Apellis Pharmaceuticals. Which major investors are buying Apellis Pharmaceuticals stock? APLS stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Candriam Luxembourg S.C.A., Opaleye Management Inc., Sphera Funds Management LTD., Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc. and Citadel Advisors LLC. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Global Strategic Fund I Venbio, Lukas Scheibler and Morningside Venture Investment. View Insider Buying and Selling for Apellis Pharmaceuticals. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Apellis Pharmaceuticals' stock price today? One share of APLS stock can currently be purchased for approximately $18.76. How big of a company is Apellis Pharmaceuticals? Apellis Pharmaceuticals has a market capitalization of $1.01 billion. The company earns $-51,000,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Apellis Pharmaceuticals employs 39 workers across the globe. What is Apellis Pharmaceuticals' official website? The official website for Apellis Pharmaceuticals is http://www.apellis.com. How can I contact Apellis Pharmaceuticals? Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected] MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 103 (Vote Outperform)Underperform Votes: 74 (Vote Underperform)Total Votes: 177MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?